Successful treatment of metronidazole- and albendazole-resistant giardiasis with nitazoxanide in a patient with acquired immunodeficiency syndrome.
A case of metronidazole- and albendazole-resistant giardiasis in a patient with the acquired immunodeficiency syndrome was successfully treated with nitazoxanide (1.5 g twice a day for 30 days). Animal studies and in vitro assays showed that the isolate was resistant to both metronidazole and albendazole and susceptible to nitazoxanide.
Abboud
P
P
Service de Maladies Infectieuses, Centre Hospitalier Universitaire Ch. Nicolle, Rouen, France.
Lemée
V
V
Gargala
G
G
Brasseur
P
P
Ballet
J J
JJ
Borsa-Lebas
F
F
Caron
F
F
Favennec
L
L
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D000328:Adult; D015766:Albendazole / Q000494:pharmacology*; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D016829:Giardia lamblia / Q000187:drug effects / Q000302:isolation & purification; D005873:Giardiasis / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000494:pharmacology*; D009574:Nitro Compounds; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D009574:Nitro Compounds; D013844:Thiazoles; D008795:Metronidazole; D015766:Albendazole; C041747:nitazoxanide